Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse, mehr …
xn--gtsel-kva.de/content/36257/novo-nordisk-a-s-trading-in-novo-nordisk-shares-by-board-members-executives-and-associated-persons.html
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the Novo Seven (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding (uterotonics) are insufficient to stop the bleeding, mehr …
xn--gtsel-kva.de/content/41695/heavy-bleeding-after-giving-birth-is-globally-a-leading-cause-of-death-in-new-mothers.html
Planta Corps Eigenmarke Acti Novo liefert Gesundheit mit dem Versprechen von Qualität
Schnelle, hochwertige Umsetzung der Produkte »Made in Germany«, mehr …
xn--gtsel-kva.de/content/43382/planta-corps-eigenmarke-acti-novo-liefert-gesundheit-mit-dem-versprechen-von-qualitaet.html
Novo Nordisk A/S: Share repurchase programme
On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
xn--gtsel-kva.de/content/37458/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk A/S, Share Repurchase Programme
On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
xn--gtsel-kva.de/content/43106/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk to Expand R & D Presence in Greater Boston Area
Novo Nordisk just announced plans to expand its research and development (R & D) presence in the greater Boston metro area, creating one of its largest R & D hubs outside of Denmark, mehr …
xn--gtsel-kva.de/content/60535/novo-nordisk-to-expand-r-und-d-presence-in-greater-boston-area.html
Novo Nordisk A/S, Share repurchase programme
On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
xn--gtsel-kva.de/content/34308/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk A/S, Share repurchase programme
This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021, mehr …
xn--gtsel-kva.de/content/34754/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk achieves primary objectives of Onwards 1 and 6 trials
Novo Nordisk today announced headline results from the main phases of Onwards 1 (52 weeks) and Onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec, mehr …
xn--gtsel-kva.de/content/44467/novo-nordisk-achieves-primary-objectives-of-onwards-1-and-6-trials.html
Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001—a cell therapy designed to restore heart function in people with advanced heart failure
HS 001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs), mehr …
xn--gtsel-kva.de/content/58964/heartseed-and-novo-nordisk-announce-first-patient-dosed-in-clinical-study-with-hs-001-a-cell-therapy-designed-to-restore-heart-function-in-people-with-advanced-heart-failure.html
Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines
Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH), mehr …
xn--gtsel-kva.de/content/38647/novo-nordisk-expands-research-collaboration-in-novel-delivery-technologies-for-biologic-medicines.html
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
xn--gtsel-kva.de/content/39024/novo-nordisk-major-shareholder-announcement.html
Novo Nordisk—major shareholder announcement
Novo Nordisk today announced that the company has been notified by Black Rock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5 percent of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
xn--gtsel-kva.de/content/44672/novo-nordisk-major-shareholder-announcement.html
Once-weekly insulin icodec demonstrates superior reduction in HbA1c
Mehr …
p style="line-height:150%;">xn--gtsel-kva.de/content/51554/once-weekly-insulin-icodec-demonstrates-superior-reduction-in-hba1c.html
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
xn--gtsel-kva.de/content/36829/novo-nordisk-major-shareholder-announcement.html
Novo Nordisk A/S, Share repurchase programme
The execution of Novo Nordisk A/S’ overall share repurchase programme for 2022 of DKK 24 billion continues, mehr …
xn--gtsel-kva.de/content/53353/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities, mehr …
xn--gtsel-kva.de/content/54158/novo-nordisk-invests-dkk-5-4-bn-danish-kroner-in-expansion-of-clinical-manufacturing-facilities-in-bagsv-aelig-rd-denmark.html
»ApoRisk«: Apotheken Nachrichten vom 18. Dezember 2023 – Update
»Entdecken Sie die dynamische Entwicklung, wegweisende Forschung und die bedeutendsten Herausforderungen, die die Apothekenlandschaft prägen.«, mehr …
xn--gtsel-kva.de/content/80632/aporisk-apotheken-nachrichten-vom-18-dezember-2023-update.html
Novo Nordisk files annual report with the SEC
Novo Nordisk A/S has filed its Annual Report 2021 on Form 20-F for the financial year 2021 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2021, mehr …
xn--gtsel-kva.de/content/36121/novo-nordisk-files-annual-report-with-the-sec.html
Forscher entschlüsseln neues Antibiotikum, Rheinische Friedrich Wilhelms Universität Bonn
Immer mehr bakterielle Krankheitserreger entwickeln Resistenzen. Die Gefahr nimmt zu, dass gängige Medikamente nicht mehr gegen Infektionskrankheiten wirken. Forscher der Universität Bonn, des Deutschen Zentrums für Infektionsforschung (DZIF), der Universität Utrecht (Niederlande), der Northeastern University in Boston (USA) und der Firma NovoBiotic Pharmaceuticals in Cambridge (USA) haben nun gemeinsam ein neues Antibiotikum entdeckt und seine Wirkweise aufgeklärt, mehr …
xn--gtsel-kva.de/content/73093/forscher-entschluesseln-neues-antibiotikum-rheinische-friedrich-wilhelms-universitaet-bonn.html
Stefan Kühn: Der Ozempic Hype! Das Diabetes Medikament Ozempic macht als Schlankheitsmittel Furore
Stefan Kühn, Betriebswirt und Ökonom, beleuchtet den Ozempic Hype: »Das Diabetes Medikament Ozempic hat nicht nur einen wichtigen Durchbruch in der Behandlung von Diabetikern erzielt«, mehr …
xn--gtsel-kva.de/content/80532/stefan-kuehn-der-ozempic-hype-das-diabetes-medikament-ozempic-macht-als-schlankheitsmittel-furore.html
Abnehmen mit Semaglutid: neue Hoffnung oder neuer Flop?
Die US-Arzneimittelbehörde FDA hat im Juni 2021 Semaglutid zur Gewichtskontrolle bei Erwachsenen ab einem BMI von 27 zugelassen, mehr …
xn--gtsel-kva.de/content/33954/abnehmen-mit-semaglutid-neue-hoffnung-oder-neuer-flop.html
Financial report for the period 1 January 2021 to 31 December 2021
Operating profit increased by 8% in Danish kroner and by 13% at constant exchange rates (CER) to DKK 58.6 billion, mehr …
xn--gtsel-kva.de/content/36087/financial-report-for-the-period-1-january-2021-to-31-december-2021.html
Gütersloh, Physiotherapie, United Therapy führt die Physiotherapie in die digitale Zukunft
Starke Partner formieren sich zu United Therapy, mehr …
xn--gtsel-kva.de/content/44540/guetersloh-physiotherapie-united-therapy-fuehrt-die-physiotherapie-in-die-digitale-zukunft.html
Neuer Wirkstoff-Kandidat für die Behandlung des Typ 2 Diabetes entwickelt
Forscher von Helmholtz Munich, dem Deutschen Zentrum für Diabetesforschung (DZD) und Novo Nordisk haben eine neue Hormon Kombination für die künftige Behandlung des Typ 2 Diabetes entwickelt, mehr …
xn--gtsel-kva.de/content/49392/neuer-wirkstoff-kandidat-fuer-die-behandlung-des-typ-2-diabetes-entwickelt.html
